ADMA BIOLOGICS, INC. (ADMA)
ADMA Biologics manufactures plasma-derived immunoglobulins and immunological therapies for hospitals and specialty practices. Sourcing material from donated human plasma, the company produces intravenous immunoglobulins and other critical-care treatments, positioning itself in the niche intersection of biotech manufacturing and hospital distribution.
Manufacturing Platform
ADMA operates plasma collection and manufacturing infrastructure aimed at supplying immunological medicines to U.S. healthcare systems. The company’s principal products focus on immunoglobulin therapies—antibody-based treatments used to treat immune deficiencies and inflammatory conditions. As a smaller player in the immunoglobulin space, ADMA competes against larger producers and faces inherent challenges around supply chain consistency, regulatory compliance, and the economics of human plasma sourcing.
The Hospital and Specialty Care Market
Immunoglobulin products serve a defined customer base: hospital intensive-care units, immunology clinics, and specialty pharmacies treating patients with primary immune deficiencies, secondary immune deficiencies, and acute inflammatory disorders. The demand for these therapies is stable and largely non-discretionary—these are not elective treatments. However, the market is consolidated, prices are under pressure from healthcare systems negotiating on volume, and regulatory oversight of biopharmaceutical manufacturing is rigorous.
At a glance
- Specialty pharmaceutical manufacturer of plasma-derived immunoglobulins
- Products used in hospital ICUs and specialty immunology clinics
- Dependent on supply of human plasma and FDA compliance
- Smaller scale competitor in a capital-intensive, highly regulated sector
- 10-K filings track manufacturing capacity and licensure status